The Zitelman Group announced today it has led a $600,000 Series B Preferred equity round for Israel-based medical device firm, Flexicath, Ltd. Flexicath received a 510(k) clearance from FDA in October, allowing it to place its FirmGrip(TM) sterile catheter intravenous (IV) system in the U.S. market. The funding will be used to ramp-up U.S. and international sales and marketing for the FirmGrip(TM) catheter.
The patent pending Flexicath FirmGrip(TM) is designed to meet the market needs for the largest segment of IV catheterizations, those lasting up to 29 days. FirmGrip(TM) may save the need for a sterile sheet by enclosing the catheter in a special self-contained package that permits insertion without removing the catheter from the sterilized coating sleeve until the procedure is complete and the catheter is in the vein.
Click here for the full story.